

REMARKS

Applicant respectfully requests entry of the above amendments. Claims 11, 13, 15-18, 20, and 25 are pending. Claims 1-10 were previously cancelled. Claims 11, 13, 15-18, and 20 were amended; claims 12 and 22-24 were withdrawn; claims 14, 19, and 21 were cancelled; and claim 25 is new; without waiver or prejudice, to comply with the restriction requirement. Applicant respectfully requests rejoinder of the withdrawn claims 12 and 22-24 at such time as the Examiner has determined that the composition claims are allowable.

Restriction/Election Requirement.

The Examiner has required restriction of the instant application to one of three Groups as set forth in the Office Action. The Groups are not reproduced herein. Applicant hereby elects Group I, claims drawn to a method of improving anesthesia recovery comprising administering a NK-1 receptor antagonist. The Examiner has further required the election of a single species. Similarly, the species are not reproduced herein. Applicant hereby elects species 1, particular compounds of Formula 1. The amended claims are drawn to Group 1 and species 1.

Conclusion

Applicants, having responded to all points and concerns raised by the Examiner and believes this application to be in condition for allowance. An early and favorable action is respectfully requested.

Respectfully submitted,

Date: November 4, 2008

/Paul M. Misiak/
Paul M. Misiak
Attorney for Applicants
Reg. No. 58,310

Pfizer Inc.
Patent Department
Eastern Point Road MS 8260-1611
Groton, CT 06340
(860) 686-9137 (phone)
(860) 441-5221 (fax)